Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Dermata Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 11 | 8 | −3 |
| Shares | 130.2K | 72.7K | −57.5K (−44.2%) |
| Value | $226.0K | $91.0K | −$135.0K (−59.7%) |
New holders (1)
Institutions that held Dermata Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 4,323 | $5.00K | 0.00% |
Sold out (4)
Institutions that held Dermata Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Renaissance Technologies LLC | 39,248 | $68.0K |
| Two Sigma Investments, LP | 18,697 | $33.0K |
| Sage Capital Advisors,llc | 12,000 | $20.0K |
| Total Clarity Wealth Management, Inc. | 500 | $1.00K |